CEBU 2018
The 3rd APAGE Clinical IBD Forum
Cebu City, Philippines
September 20 - 22, 2018

Visit our website: www.apageibdcebu.org | Abstract submission deadline: July 1, 2018
CEBU 2018 – THE APAGE 3RD CLINICAL FORUM ON IBD
20th to 22nd September 2018, Radisson Blu Hotel, Cebu City, Philippines

ORGANIZING COMMITTEE

**Overall Chairpersons**
Choon Jin Ooi
Jose Sollano

**Scientific Committee**
Ida Hilmi
Vineet Ahuja
Khoon Lin Ling
Evan Ong

<table>
<thead>
<tr>
<th>National Advisers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Judith Gapasin-Tongco</td>
</tr>
<tr>
<td>President, Philippine Society of Gastroenterology</td>
</tr>
<tr>
<td>Dennis Ona</td>
</tr>
<tr>
<td>Leticia Guzman</td>
</tr>
<tr>
<td>Mark Anthony de Lusong</td>
</tr>
<tr>
<td>Lamberto Garcia Jr</td>
</tr>
<tr>
<td>Albert Ismael</td>
</tr>
</tbody>
</table>
# CEBU 2018 – THE APAGE 3rd Clinical Forum on IBD
20th to 22nd September 2018, Radisson Blu Hotel, Cebu City, Philippines

## Invited Faculty & Chairpersons

### Australia
- Peter Gibson
- Michael Kamm
- Rupert Leong

### China
- Min Hu Chen
- Zhi Hua Ran
- Kai Chun Wu

### Hong Kong
- Wai Keung Leung
- Siew Chien Ng

### India
- Vineet Ahuja
- Rupa Banerjee
- Govind Makharia
- Ajit Sood

### Indonesia
- Murdani Abdullah

### Japan
- Toshifumi Hibi
- Tadakazu Hisamatsu
- Taku Kobayashi
- Katsuyoshi Matsuoka

### Korea
- Won Ho Kim
- Dong Il Park
- Byong Duk Ye

### Malaysia
- Alex Leow
- Nazri Mustaffa
- Raja Affendi Raja Ali

### Myanmar
- Than Than Aye

### Philippines
- Lamberto Garcia Jr
- Leticia Guzman
- Karen de Lunas
- Evan Ong
- Jose Sollano
- Carla Tablante

### Singapore
- Sai Wei Chuah
- Christopher Khor
- Wee Chian Lim
- Khoon Lin Ling
- David Ong
- Choon Jin Ooi

### Thailand
- Varocha Mahachai
- Pises Pisespongsa

### Taiwan
- Shu Chen Wei

### United Kingdom
- Peter Irving
CEBU 2018 – THE APAGE 3RD CLINICAL FORUM ON IBD
20th to 22nd September 2018, Radisson Blu Hotel, Cebu City, Philippines

DAILY PROGRAMME
20th September 2018 (Thursday)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800</td>
<td>PHILIPPINE SOCIETY OF GASTROENTEROLOGY MIDYEAR CONVENTION</td>
</tr>
<tr>
<td>1730</td>
<td>OPENING DINNER SYMPOSIUM <em>(Ferring Pharmaceuticals)</em></td>
</tr>
<tr>
<td>1830</td>
<td>OPENING CEREMONY &amp; WELCOME ADDRESS</td>
</tr>
<tr>
<td></td>
<td>• Kentaro Sugano, President, Asian Pacific Association of Gastroenterology</td>
</tr>
<tr>
<td></td>
<td>• Judith D Gapasin-Tongco, President, Philippine Society of Gastroenterology</td>
</tr>
<tr>
<td></td>
<td>• Dennis Ona, President, Philippine Society of Digestive Endoscopy</td>
</tr>
<tr>
<td></td>
<td>• Jose D Sollano, Local Organising Chairman</td>
</tr>
<tr>
<td></td>
<td>• Choon Jin Ooi, Organising Chairman</td>
</tr>
</tbody>
</table>

DAILY PROGRAMME
21st September 2018 (Friday)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800</td>
<td>PRE-CONGRESS WORKSHOP 1 <em>(Concurrent)</em> Endoscopic Therapy in IBD</td>
</tr>
<tr>
<td>0800</td>
<td>PRE-CONGRESS WORKSHOP 2 <em>(Concurrent)</em> Fecal Microbiota Transplant Workshop</td>
</tr>
<tr>
<td>0930</td>
<td>MID-MORNING SYMPOSIUM</td>
</tr>
<tr>
<td>1030</td>
<td>SESSION 1</td>
</tr>
<tr>
<td></td>
<td>Disease Modifying Drugs in IBD: The End of the Beginning</td>
</tr>
<tr>
<td>1100</td>
<td>SESSION 2</td>
</tr>
<tr>
<td></td>
<td>Biologics are Forever – A Tale of Two Experts</td>
</tr>
<tr>
<td>1130</td>
<td>FREE PAPER SESSION <em>(10 minutes per presentation)</em></td>
</tr>
<tr>
<td>1200</td>
<td>LUNCH SYMPOSIUM</td>
</tr>
<tr>
<td>1315</td>
<td>TRADE EXHIBITION</td>
</tr>
<tr>
<td>1330</td>
<td>SESSION 3</td>
</tr>
<tr>
<td></td>
<td>Assessment and Monitoring of the IBD Patient</td>
</tr>
<tr>
<td>1330</td>
<td>Small bowel imaging for Cohn’s disease - Capsule, enteroscopy or MRI?</td>
</tr>
<tr>
<td>1350</td>
<td>Comparison between the current fecal markers for IBD</td>
</tr>
<tr>
<td>1410</td>
<td>How do we treat and follow up patients with mild IBD?</td>
</tr>
<tr>
<td>1445</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>1445</td>
<td>HI-TEA SYMPOSIUM</td>
</tr>
<tr>
<td>1545</td>
<td>SESSION 4</td>
</tr>
<tr>
<td></td>
<td>Systemic Complications in IBD and IBD Therapy</td>
</tr>
<tr>
<td>1545</td>
<td>Fertility and pregnancy related issues in IBD</td>
</tr>
<tr>
<td>1605</td>
<td>Extracolonic malignancies in IBD</td>
</tr>
<tr>
<td>1625</td>
<td>Approach to deranged LFTs in the IBD patient</td>
</tr>
<tr>
<td>1645</td>
<td>Management of joint related manifestations in IBD</td>
</tr>
<tr>
<td>1705</td>
<td>Q &amp; A</td>
</tr>
</tbody>
</table>

Page 1 of 2
DAILY PROGRAMME
22nd September 2018 (Saturday)

0800 – 0915  SESSION 5
Nutrition
0800 – 0820  Diet and IBD – What your patients want to know
0820 – 0840  Probiotics, prebiotics and symbiotics in IBD
0840 – 0900  Management of short gut syndrome
0900 – 0915  Q & A

0915 – 1015  MID-MORNING SYMPOSIUM

1015 – 1130  SESSION 6
Controversial Issues in IBD Surgery
1015 – 1035  Prevention and management of post-operative recurrence in Crohn’s disease – Do we finally have a standard of care?
1035 – 1055  Colectomy versus endoscopic therapy for colitis associated dysplasia
1055 – 1115  Rescue therapy in acute severe colitis – How far can you go?
1115 – 1130  Q & A

1130 – 1245  LUNCH SYMPOSIUM

1245 – 1300  TRADE EXHIBITION

1300 – 1415  SESSION 7
Emerging Therapies in IBD
1300 – 1320  ‘Thinking outside the box’ – Curcumin and alternative therapies in IBD
1320 – 1340  New kids on the block – The role of small molecules in IBD
1340 – 1400  Latest advances in the management of perianal fistulas – Beyond biologics
1400 – 1415  Q & A

1415 – 1515  SESSION 8
Challenging Cases in IBD (with interactive voting system)
1415 – 1445  Case I
1445 – 1515  Case II

1515 – 1615  HI-TEA SYMPOSIUM

1615 – 1730  SESSION 9
APAGE/AOCC SYMPOSIUM (with interactive voting system)
1615 – 1635  Tuberculosis and Biologic Therapy
• Reactivation of tuberculosis – How do the available biologics measure up?
• Consensus guidelines on screening and treatment
1635 – 1655  Therapeutic Drug Monitoring in IBD
• Differences in thiopurine pharmacogenetic profile between Asian and Caucasian populations
• Consensus guidelines for pharmacogenetics testing and therapeutic drug monitoring
1655 – 1715  Screening for Infection
• Screening and prophylaxis for chronic hepatitis B in patients on biologic therapy
• Should screening for EBV be incorporated into our Asian setting?
1715 – 1730  Q & A

1730 – 1745  PRIZE AWARD & CLOSING REMARKS